NASDAQ:VYGR
Voyager Therapeutics Stock News
$8.43
-0.200 (-2.32%)
At Close: May 17, 2024
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
03:25pm, Friday, 08'th Mar 2024
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcript
11:02pm, Wednesday, 28'th Feb 2024
Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcript
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
04:01pm, Wednesday, 28'th Feb 2024
- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering -
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
03:20pm, Monday, 26'th Feb 2024
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint ste
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
07:00am, Wednesday, 21'st Feb 2024
LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fou
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
07:00am, Wednesday, 07'th Feb 2024
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financi
Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024
10:09pm, Thursday, 11'th Jan 2024
The financial markets in 2024 will be pulsating with transformative opportunities driven by companies poised to redefine industries. This is leading to several 2024 investment trends making themselves
Voyager Therapeutics stock pops 30% on deal with Novartis
09:25am, Monday, 08'th Jan 2024
Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with Novart
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
12:47pm, Wednesday, 03'rd Jan 2024
Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
Voyager Therapeutics' Novartis deal has analysts bullish on stock's long-term outlook
02:56pm, Tuesday, 02'nd Jan 2024
Voyager Therapeutics' announcement that it has entered into an additional up to $1.2 billion collaboration with Novartis AG (ADR) (NYSE:NVS) for its TRACER capsids to develop potential gene therapies
Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments
02:20pm, Tuesday, 02'nd Jan 2024
Shares of Voyager Therapeutics Inc. (VYGR) jumped Tuesday after the biotech firm agreed to a strategic collaboration and capsid licensing agreement with Novartis AG (NVS) to treat neurological illness
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
10:46am, Tuesday, 02'nd Jan 2024
Voyager Therapeutics (NASDAQ: VYGR ) stock is up by more than 25% today after the company agreed to a licensing deal with Novartis (NYSE: NVS ). Novartis will pay $100 million upfront in a “target-e
Voyager Therapeutics shares pop on collaboration with Novartis worth up to $1.2B
07:58am, Tuesday, 02'nd Jan 2024
Voyager Therapeutics Inc (NASDAQ:VYGR) shares rallied more than 30% in Tuesday pre-market trading after the company announced a strategic collaboration and capsid license agreement worth up to $1.2 bi
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
12:03pm, Sunday, 17'th Dec 2023
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital